These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22773601)

  • 1. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
    van Dussen L; Cox TM; Hendriks EJ; Morris E; Akkerman EM; Maas M; Groener JE; Aerts JM; Deegan PB; Hollak CE
    Haematologica; 2012 Dec; 97(12):1850-4. PubMed ID: 22773601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
    Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
    Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
    Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
    Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM; Rosenbloom B; Weinreb N; Goker-Alpan O; Grabowski G; Cohn GM; Zahrieh D
    Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
    Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
    Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
    Ida H; Tanaka A; Matsubayashi T; Murayama K; Hongo T; Lee HM; Mellgard B
    Blood Cells Mol Dis; 2016 Jul; 59():140-7. PubMed ID: 27241455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
    Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.
    Pleat R; Cox TM; Burrow TA; Giraldo P; Goker-Alpan O; Rosenbloom BE; Croal LR; Underhill LH; Gaemers SJ; Peterschmitt MJ
    Mol Genet Metab Rep; 2016 Dec; 9():25-28. PubMed ID: 27722092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
    Hughes DA; Gonzalez DE; Lukina EA; Mehta A; Kabra M; Elstein D; Kisinovsky I; Giraldo P; Bavdekar A; Hangartner TN; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):584-91. PubMed ID: 25801797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.